Maura R V Ikoma-Colturato1, Miriam P Beltrame2, Felipe M Furtado3, Glicinia Pimenta4, Elaine Sobral da Costa4, Ana Paula Azambuja5, Mariester Malvezzi5, Mihoko Yamamoto6. 1. Hospital Amaral Carvalho, Jaú, SP, Brazil; Sabin Medicina Diagnóstica, Brasília, DF, Brazil. Electronic address: maura.ikoma@amaralcarvalho.org.br. 2. Hospital Erasto Gaertner, Curitiba, PR, Brazil. 3. Sabin Medicina Diagnóstica, Brasília, DF, Brazil; Hospital da Criança de Brasília José de Alencar, Brasilia, DF, Brazil, Brazil. 4. Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil. 5. Hospital de Clínicas Universidade Federal do Paraná (UFPR), Curitiba, PR, Brazil. 6. Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil.
Abstract
INTRODUCTION: The minimal residual disease (MRD) status plays a crucial role in the treatment of acute lymphoblastic leukemia (ALL) and is currently used in most therapeutic protocols to guide the appropriate therapeutic decision. Therefore, it is imperative that laboratories offer accurate and reliable results through well standardized technical processes by establishing rigorous operating procedures. METHOD: Our goal is to propose a monoclonal antibody (MoAb) panel for MRD detection in ALL and provide recommendations intended for flow cytometry laboratories that work on 4-color flow cytometry platforms. RESULTS AND CONCLUSION: The document includes pre-analytical and analytical procedures, quality control assurance, technical procedures, as well as the information that needs to be included in the reports for clinicians.
INTRODUCTION: The minimal residual disease (MRD) status plays a crucial role in the treatment of acute lymphoblastic leukemia (ALL) and is currently used in most therapeutic protocols to guide the appropriate therapeutic decision. Therefore, it is imperative that laboratories offer accurate and reliable results through well standardized technical processes by establishing rigorous operating procedures. METHOD: Our goal is to propose a monoclonal antibody (MoAb) panel for MRD detection in ALL and provide recommendations intended for flow cytometry laboratories that work on 4-color flow cytometry platforms. RESULTS AND CONCLUSION: The document includes pre-analytical and analytical procedures, quality control assurance, technical procedures, as well as the information that needs to be included in the reports for clinicians.
Authors: G E Broto; P R B Silva; F C Trigo; V J Victorino; K L Bonifácio; W R Pavanelli; F Tomiotto-Pelissier; M R Garbim; S T Oliveira; J J Jumes; C Panis; D S Barbosa Journal: Curr Res Immunol Date: 2021-10-08